Last update Oct. 21, 2024

Dapagliflozin

Likely Compatibility

Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.

Dapagliflozin is a selective and reversible inhibitor of the sodium and glucose co-transporter 2 (SGLT2). It acts by reducing the renal reabsorption of glucose and increasing its elimination via urine (Kasichayanula 2014, Plosker 2014). Administered orally once a day.

Since the last update, we have not found published data on its excretion in breast milk.

Its pharmacokinetic characteristics: moderately elevated molecular weight, high plasma protein binding and large volume of distribution (EMA 2017), make it very unlikely its excretion into breast milk in significant amounts.

It has a low risk of hypoglycemia in monotherapy, which increases when it is associated with other hypoglycaemic agents. (EMA 2017, Plosker 2014)

Until there is more published data on this drug in relation to breastfeeding, safer known alternatives may be preferable, especially during the neonatal period and in case of prematurity. Diet, exercise and breastfeeding improve blood glucose levels.


See below the information of this related product:

  • Maternal Diabetes mellitus (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)

Alternatives

  • Acarbose (Safe product and/or breastfeeding is the best option.)
  • Glibenclamide (Safe product and/or breastfeeding is the best option.)
  • Glipizide (Safe product and/or breastfeeding is the best option.)
  • Hypocaloric Diet (Safe product and/or breastfeeding is the best option.)
  • Maternal Sport (Safe product and/or breastfeeding is the best option.)
  • Metformin Hydrochloride (Safe product and/or breastfeeding is the best option.)
  • Miglitol (Safe product and/or breastfeeding is the best option.)
  • Tolbutamide (Safe product and/or breastfeeding is the best option.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Dapagliflozin is also known as


Dapagliflozin in other languages or writings:

Groups

Dapagliflozin belongs to these groups or families:

Tradenames

Main tradenames from several countries containing Dapagliflozin in its composition:

List of 10 tradenames

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 78 %
Molecular weight 409 daltons
Protein Binding 91 %
VD 1.7 l/Kg
Tmax 1 - 2 hours
T½ 12.9 - 13.8 hours

References

  1. EMA. Dapagliflozin. Drug Summary. 2017 Full text (in our servers)
  2. EMA. Dapagliflozina. Ficha técnica. 2017 Full text (in our servers)
  3. Kasichayanula S, Liu X, Lacreta F, Griffen SC, Boulton DW. Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Abstract
  4. Plosker GL. Dapagliflozin: a review of its use in patients with type 2 diabetes. Drugs. 2014 Abstract

Total visits

11,975

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by IHAN of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM